NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-HL-18-662 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-NS-19-014 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) supports the development of PET radioligands that identify proteinopathies or pathological processes associated with the human biology of Alzheimer's disease related dementias (ADRDs). Activities supported under this FOA include, but are not limited to the in vitro screening of existing ligands against human ADRD brain tissue, medicinal chemistry support for development of new compounds and improvement of existing ligand specificity and selectivity, initial screening of ligands in appropriate animal models, and radioligand formulation and first-in-human testing. The Center without Walls should encompass research that will move promising ligands through in vitro and in vivo optimization to first-in-human studies. Applications must include an administrative core, a medicinal chemistry core, a clinical core, a scientific governance structure, and a minimum of two research projects with milestone plans that address workflows for screening of existing and newly derived ligands against human ADRD tissue and appropriate animal models. Synergy must be evident among Center research projects and cores, such that successful completion of the aims could not be accomplished without the Center structure. This FOA is in response to the Alzheimer's Disease Related Dementias (ADRD) challenges outlined in the 2016 update to the National Plan to Address Alzheimer's Disease.
Funding Opportunity PAR-19-098 from the NIH Guide for Grants and Contracts. This is a reissue of the Emerging Global Leader Program (K43) to align with the clinical trials policy.
Notice NOT-HL-18-669 from the NIH Guide for Grants and Contracts
Notice NOT-EB-18-034 from the NIH Guide for Grants and Contracts
Notice NOT-HL-18-668 from the NIH Guide for Grants and Contracts
Notice NOT-MH-18-074 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AA-19-003 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) seeksl applications for a research center grant to conduct cross-cutting research on alcohol and HIV/AIDS. Through this FOA, NIAAA seeks to encourage research that can be translated into interventions in order to reduce infection and transmission of HIV. The FY2013 Trans-NIH Plan For HIV-Related Research (http://www.oar.nih.gov/strategicplan/fy2013/index.asp) describes the goals of highest priority.
Notice NOT-MH-19-003 from the NIH Guide for Grants and Contracts
Notice NOT-OD-19-040 from the NIH Guide for Grants and Contracts
Notice NOT-OD-19-041 from the NIH Guide for Grants and Contracts
Notice NOT-AI-19-016 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DA-19-035 from the NIH Guide for Grants and Contracts. This FOA is intended to solicit two-phase research applications to develop, adapt and test interventions and strategies to prevent initiation of opioid misuse and development of OUD in at-risk older adolescents and young adults (ages 16-30). The goal is to stimulate research studies conducted in populations and geographic areas most affected by the opioid crisis or with indicators of an emerging crisis. Of priority are studies that target older adolescents and young adults in health care settings (including primary care, surgical, orthopedic and other specialty care, dental care, emergency departments, urgent care, HIV/STI and reproductive health clinics, prenatal clinics, school-based health centers, federally qualified health centers, military medicine settings, occupational health settings), justice settings (including criminal justice, juvenile justice, as well as child welfare and other systems that cross with the justice system) and other systems and settings. Studies that include understudied at-risk older adolescent and young adult populations are strongly encouraged. Examples include, but are not limited to individuals in rural or reservation settings, women, veterans, and individuals with a history of polysubstance use or mental disorders.
Funding Opportunity RFA-NS-19-021 from the NIH Guide for Grants and Contracts. The Purpose of this FOA is to solicit cooperative agreement applications that propose clinical trials to establish the effectiveness of existing therapies and approaches for prevention and management of pain. The studies must address questions within the mission and research interests of participating NIH Institutes and Centers and evaluate preventive strategies or interventions including medications, biologics, procedures, medical and assistive devices and technologies, diagnostic testing, behavioral change, rehabilitation strategies, complementary therapies, integrated approaches, and delivery system strategies in well controlled trials The overall goal is to inform clinicians about the effectiveness of interventions that will improve functional outcomes and reduce pain across the continuum of acute to chronic pain associated with many types of diseases or conditions or pain presenting as a disease itself. Clinical trials will be conducted within the infrastructure of the HEAL Pain Management Effectiveness Research Network.
Funding Opportunity RFA-RM-19-001 from the NIH Guide for Grants and Contracts. The purpose of this NIH Funding Opportunity Announcement (FOA) is to invite research applications proposing to map neural circuitry mediating visceral organ pain. This FOA is part of the Stimulating Peripheral Activity to Relieve Conditions (SPARC) Common Fund program and is coordinated with the Translational Devices to Treat Pain (TDTP) initiatives of the NIH HEAL program (see Companion Funding Opportunities above). Detailed mapping of pain-mediating circuitry originating from visceral organ afferents will leverage the SPARC program to produce maps that could accelerate the development of non-addictive approaches to treat pain.
Funding Opportunity RFA-TR-19-005 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support intramural-extramural collaborations to develop and implement the use of 3D biofabricated tissue models as novel drug screening platforms and advance pre-clinical discovery and development of non-addictive treatments for nociception, opioid use disorder (OUD) and/or overdose. In particular, support during the UH2 phase is for the application of 3D biofabrication technologies to develop novel multicellular tissue constructs for drug screening by using human iPSC-derived cells representing sensory/pain neurons, brain regions, and other tissues involved in nociception, addiction and/or overdose, including tissue models of the blood-brain barrier (BBB). Support during the UH3 is for implementation of drug screens using the 3D tissue models developed during the UH2 phase. Please limit this field to a brief description of to page in length. Brevity is appreciated. This FOA is part of the of the NIHs Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions to the national opioid public health crisis. The NIH HEAL Initiative will bolster research across NIH to (1) improve treatment for opioid misuse and addiction and (2) enhance pain management. More information about the HEAL Initiative is available at: https://www.nih.gov/research-training/medical-research-initiatives/heal-initiative
Funding Opportunity RFA-TR-19-003 from the NIH Guide for Grants and Contracts. Tissue This FOA will provide funding for Investigators to create and test devices that can model the mechanisms or effects of nociception/pain-relevant signaling, addiction, or opioid use disorders (OUDs), using human tissues in in vitro microphysiological systems (MPS). Tissue chips, or microphysiological systems, are useful and promising in vitro human-based screening platforms because they closely mimic in vivo human physiology. Tissue chips have been shown to be capable of modeling normal and diseased physiology that faithfully recapitulates responses to stressors, treatments and other perturbations. This FOA is part of the of the NIHs Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions to the national opioid public health crisis. The NIH HEAL Initiative will bolster research across NIH to (1) improve treatment for opioid misuse and addiction and (2) enhance pain management. More information about the HEAL Initiative is available at: https://www.nih.gov/research-training/medical-research-initiatives/heal-initiative.
Funding Opportunity RFA-NS-19-020 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to support preclinical optimization and development of safe, effective, and non-addictive small molecule and biologic therapeutics to treat pain. The goal of the program is to accelerate the optimization and development of promising small molecule and biologic hits/leads towards clinical trials. Applicants must have a promising hit/lead, robust biological rationale for the intended approach, and identified assays for optimization of the agent. The scope of this program includes optimization and early development activities, IND-enabling studies, and assembly of Investigational New Drug (IND) application. This is a milestone-driven phased cooperative agreement program involving participation of NIH program staff in the development of the project plan and monitoring of research progress.
Funding Opportunity RFA-MH-19-525 from the NIH Guide for Grants and Contracts. In April 2018, the National Institutes of Health (NIH) launched the HEAL (Helping to End Addiction Long-term) Initiative, an aggressive, trans-agency effort to speed scientific solutions to stem the national opioid public health crisis. In response to this initiative, the National Institute of Mental Health (NIMH), in partnership with other NIH Institutes, proposes research to adapt the Collaborative Care Model (referred to henceforth as collaborative care) a specific service delivery model for treating mental/behavioral health conditions in primary care settings to meet the needs of individuals with opioid use disorders (OUDs) and co-occurring mental health conditions. Effectiveness clinical trials are envisioned to develop, optimize, implement, scale, and sustain collaborative models that offer Medication Assisted Treatment for OUD alongside indicated treatment for mental health conditions that commonly co-occur with OUD and are treatable in primary care.
Funding Opportunity RFA-AR-19-028 from the NIH Guide for Grants and Contracts. NIH has identified a set of research priorities reflecting urgent unmet needs across the lifespan, areas of promising scientific opportunity, and concrete strategies capable of providing rapid and durable solutions to the opioid crisis including improved understanding of the biological underpinnings of chronic pain and discovery and testing of new non-addictive pain treatments.